Plus d’un million de livres disponibles en un clic !
Mike BrileyLivres
Mike Briley est un auteur dont le parcours littéraire a été façonné par ses expériences de vie à l'étranger. Ses œuvres explorent souvent l'intersection de différentes cultures et perspectives, reflétant sa propre vie passée en Argentine et en France après ses études au Royaume-Uni. La prose de Briley se caractérise par un mélange unique de curiosité intellectuelle et d'observation perspicace, offrant aux lecteurs des aperçus sur les complexités de l'expérience humaine.
The field of molecular genetics is undergoing an explosion, not only in its fundamental understanding of the genetic processes but also in the potential applications as research tools and therapeutic approaches to many disease areas. Mental disorders are no exception and it is likely that most new psychotropic drugs will in future be derived through molecular genetic approaches. This book examines the place of molecular genetics in our understanding of the basic mechanisms of mental disorders and their role in highlighting new drug targets.
Peter Bennett's life takes a dramatic turn when he finds himself embroiled in a web of mystery and danger. As he navigates unexpected challenges, he uncovers secrets that test his resilience and moral compass. The story intricately weaves themes of friendship, betrayal, and self-discovery, showcasing Peter's transformation as he confronts both external threats and his inner demons. The narrative promises suspense and emotional depth, keeping readers engaged as they follow Peter's journey through turmoil and revelation.
For over thirty years, benzodiazepines dominated the anxiolytic market and influenced clinical and animal research in anxiety. Many animal tests developed since the 1960s were optimized for benzodiazepines, with some screening candidates based on benzodiazepine-like side effects rather than their actual anxiolytic activity. As the limitations of benzodiazepines, particularly their potential for tolerance and dependency, became apparent, interest in alternative anxiolytics grew. This includes both existing medications, such as tricyclic and monoamine oxidase antidepressants, and newer options like buspirone. Additionally, anxiety is now viewed as an umbrella term encompassing various specific disorders, including panic disorder, generalized anxiety disorder (GAD), specific phobias, social phobias, and post-traumatic stress disorder (PTSD). These new classifications necessitate tailored treatments for different anxiety syndromes. The book critically reviews current anxiolytics and potential future options. It highlights that, while benzodiazepines remain prevalent for acute anxiety, they are not the first choice for chronic anxiety. Alternatives like tricyclics, monoamine oxidase inhibitors, serotonin reuptake inhibitors, and buspirone provide better solutions for chronic anxiety, though none are yet ideal.
